change nephrotic syndrome (MCNS) (62%) followed by focal segmental glomerulosclerosis (FSGS, 27%) and IgM nephropathy (11%). Median age was 7.8 (Range 2.5 – 16.5) years with median follow up post rituximab 33 (Range 1.5 to 87) months. Rituximab was given as infusion at 375 mg / m2. Each cycle constituted of 2 injections at an interval of 1-2 weeks followed by confirmation of B cell depletion. Single cycle achieved total B-cell depletion in all. 5 cases (all SRNS) received 2. Median duration for normalisation of CD 19 was 4.65 (3 – 7) months. Among the SRNS, serum albumin rose from mean 1.87 (SD ± 0.53) to 2.63 (SD ± 1.1) g/dl, (p=0.06) and UPCR fell from mean 19.3 (SD ± 12.04) to 9.8 (SD ± 10.96) p=0.15. 20% of SRNS (n=2) achieved CR another 20% PR. Steroid threshold among SDNS/FRNS fell from mean 0.47 (SD ± 0.19) to 0.17 (SD ± 0.23) mg/kg, p=0.0003 and dose of steroid at last follow up fell men 0.88 (SD ± 0.56) to 0.22 (SD ± 0.43) mg/kg, p=0.0009. 50% of SDNS/FRNS (n=11) did not have any relapse during the follow up period and median time to first relapse was 6.6 (Range 0.3 – 25) months.

Conclusions: Rituximab was demonstrated to be useful with significant benefit particularly in the SDNS group.

## P04

**A NOVEL MOUSE MODEL OF MEMBRANOUS NEPHROPATHY INDUCED WITH HETEROLOGOUS RABBIT ANTI-THSD7A ANTIBODIES**

Tomas, N1, Meyer-Schwesinger, C1, von Spiegel, H1, Zahner, G1, Hoxha, E1, Helmchen, U2, Koch-Nolte, F3, Stahl, RAK1

1Universitätsklinikum Hamburg-Eppendorf, II. Medizinische Klinik-Nephrologie, Hamburg, Germany; 2Universitätsklinikum Hamburg-Eppendorf, Nierenregister, Hamburg, Germany; 3Universitätsklinikum Hamburg-Eppendorf, Institut für Immunologie, Hamburg, Germany

**Introduction:** Phospholipase A2 receptor 1 (PLA2R1) and thrombospondin type-1 domain-containing 7A (THSD7A) are podocyte membrane proteins that have been identified as target antigens for autoimmunity in membranous nephropathy (MN). The investigation of the pathogenicity of the involved autoantibodies has been hampered by the fact that PLA2R1 is not expressed on rodent podocytes. On the other hand, THSD7A is expressed on mouse podocytes and shares over 90% of sequence homology with the human protein. We have recently demonstrated that anti-THSD7A antibodies isolated from a patient with THSD7A- associated MN can cause morphological and clinical MN in mice, allowing further investigations of disease pathogenesis. However, THSD7A-associated MN is a rare entity, incapacitating patient antibodies for larger experimental procedures.

**Methods:** We generated polyclonal antibodies against human and mouse THSD7A in rabbits using cDNA immunization. IgG from the immunized rabbits and from preimmune control rabbits was affinity-purified and intravenously injected into mice. Urine was collected daily and investigated for the development of proteinuria by measurement of albumin-to-creatinine ratios. Mice were sacrificed five, nine, and fourteen days after injection of rabbit IgG and kidneys were analyzed using confocal and light microscopy.

**Results:** Purified IgG from immunized rabbits recognize, like patient autoantibodies, (a) conformation-dependent epitope(s) present in both native human and mouse THSD7A in vitro. Moreover, two hours after intravenous injection into mice, rabbit IgG is bound along the glomerular filtration barrier. Two days later, mice develop proteinuria that rapidly increases and reaches around 10 g/g after 5 days and 200-300 g/g albumin-to-creatinine after 14 days with some mice developing a severe nephrotic syndrome with ascites and hyperlipidemia. In immunofluorescent analysis, granular rabbit IgG is found subepitheliaally along the glomerular filtration barrier after 14 days and immunohistochemistry for rabbit IgG shows the classic picture of human MN. Mice injected with purified IgG from rabbit serum that was taken before THSD7A-immunization fail to develop any of these changes.

**Conclusions:** Our study introduces a heterologous mouse model that allows further mechanistic investigations of the molecular events leading to membranous nephropathy.

## P05

**IDENTIFICATION OF GLYCOSAMINOGLYCANS THAT SPECIFICALLY INHIBIT THE LECTIN PATHWAY OF COMPLEMENT**

Talsma, D1, Poppelelaars, F1, Vives, RR2, Lortat-Jacob, H2, Naggi, A3, Torri, G3, Seelen, M1, Daha, M1, Stegeman, CA1, van den Born, J1

1University Medical Centre Groningen, Nephrology, GRONINGEN, The Netherlands; 2Univ of Grenoble, Inst. for Structural Biology, Grenoble, France; 3Ronzoni Institute, Carbohydrate Science Group, Milano, Italy

**Introduction:** The complement system can be activated via three pathways, the classical (CP), alternative (AP) and lectin pathway (LP). Studies have shown a role for complement in renal diseases such as hemolytic uremic syndrome, C3 glomerulopathy and renal transplantation. It is well known that heparin and some other glycosaminoglycans (GAGs) inhibit complement activation. We tested the pathway specific complement inhibiting potential of >70 GAGs. The results showed that some GAGs had a specific inhibitory effect on the LP only. In this work we unravel the inhibitory mechanism of GAGs on the LP.

**Methods:** GAGs were tested in the Wieslab complement screening assay for a dose-dependent inhibition assay of the complement pathways. Inhibition of ficolin-3 mediated LP activation by GAGs was tested in the Wieslab ficolin-3 assay. To assess whether GAGs inhibit the MBL – mannan interaction, GAGs were added to diluted serum and incubated on mannan coated plates where after deposition of MBL was measured. To test the inhibition of GAGs on MASP activity, the GAGs were added to purified C4 and incubated on MBL-MASP coated plates, C4 activation was measured by detection of C4b. To assess whether the MBL-MASP complex binds to heparin, serum was incubated on heparin-albumin coated plates and binding of MBL, MASP-1 and MASP-2 was measured.

**Results:** In the Wieslab complement screening assay, (LMW-)heparin dose-dependently inhibited all three pathways of complement. Depolymerization of heparin followed by size-fractionation of the resultant oligosaccharides revealed hexasaccharides and tetrasaccharides to exclusively inhibit the LP, without any inhibition potential for the CP and AP. Heparin (oligo’s) also show a dose-dependent inhibition of the ficolin-3 mediated LP activation, however failed to inhibit the binding of MBL to mannan, indicating inhibition by GAGs of MASP1/2 enzymes. This was proven in the MASp-1/2 inhibition assays. Heparin (oligo’s) inhibited the C4 cleavage by MASP-1/2 in a dose-dependent way. Comparison of defined heparin-derived tetrasaccharides with various sulfation revealed the fully N-, O- and sulfated fragment the most potent MASP-1/2 inhibitor. Vice versa the MBL-MASP complex shows
binding to immobilized heparin-albumin, but not with albumin, likely via MASP-1/2 – heparin interaction.

**Conclusions:** Our data identifies small heparin-derived oligosaccharide inhibitors specific for the LP. We show that the LP inhibitory effect of GAGs is via blocking the enzymatic activity of the MASP enzymes. Binding of the MBL-MASP complex to immobilized heparin indicates that heparan sulfate/heparin structures on cells and in extracellular matrix in vivo might act as docking platforms for the MBL-MASP complex. These results might be important for renal diseases with LP involvement.

**P06**

**OFATUMUMAB FOR B CELL DEPLETION THERAPY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WHO ARE INTOLERANT OF RITUXIMAB**

**McAdoo, S**, S, **Masoud, S**, S, **Bedi, R**, R, **Cairns, T**, T, **Lightstone, L**

**Imperial College Healthcare NHS Trust, Renal, London, United Kingdom**

**Introduction:** B cell depletion, most commonly with rituximab (RTX), has emerged as a potential therapeutic strategy in SLE, particularly in patients who are unresponsive to, or intolerant of, standard therapy. Ofatumumab is a fully humanised anti-CD20 monoclonal antibody directed against distinct extra-cellular epitope on CD20, which has shown efficacy in the treatment of haematological malignancy. Since 2012, we have been using ofatumumab on compassionate grounds in patients with SLE for whom B cell depletion is deemed a desirable therapeutic approach, but who are allergic to RTX.

**Methods:** This is a retrospective report of SLE cases treated with ofatumumab at our centre between 2012-2015. Data are reported as medians +/- IQR, and comparisons are by non-parametric testing, unless otherwise stated.

**Results:** In total, 15 patients received ofatumumab: all female, mean age 33 years, median duration of SLE 7.5 years (range 1-18). 46% had previously been treated with cyclophosphamide and all had previously received RTX (median time since last treatment 4.5 months). All had severe infusion reactions to RTX previously. Two patients demonstrated infusions reactions to ofatumumab, such that they did not receive full dosing and have therefore been excluded from subsequent analysis.

Of the remaining 13 cases, ten were treated for disease flares complicated by lupus nephritis (LN); three patients were treated for extra-renal disease. Our standard treatment protocol is ofatumumab 2x700mg iv doses, with MMF maintenance and minimal steroids. Following treatment, two patients did not achieve B cell depletion (BCC<20). In those who did deplete, the median time to depletion was 16 days, and to subsequent reconstitution (BCC>20) 4.8 months (see Figure). Treatment was associated with significant improvements in serological markers of disease activity at 6 months (see Figure & Table).

### Summary

Three patients with LN did not respond to treatment (>1.5x rise in serum creatinine at 6 months). The remaining patients had stable renal function (<10% increase or improved serum creatinine) with improved proteinuria (median uPCR 424 to 99 mg/mmol) at 6 months. At last followup (median duration 32months), no opportunistic infections, malignancies, new episodes of hypogammaglobulinaemia, or deaths have been observed. Three patients had further severe disease flares requiring hospitalisation and escalation of treatment.

**Conclusions:** In this heavily pre-treated cohort, with longstanding SLE refractory to conventional treatment, ofatumumab was effective for B cell depletion in patients who were intolerant of rituximab. Treatment was associated with serological and clinical response, although a proportion of patients had progressive disease. No unexpected safety signals were seen. Larger controlled studies are desirable to further define the role of ofatumumab in the treatment of SLE. Pending these studies, ofatumumab may be considered for patients who are intolerant of RTX, and for whom B cell depletion is still a desirable treatment strategy.

**P07**

**SHOULD PATIENTS UNDERGOING RENAL TRANSPLANT WITHOUT INDUCTION WITH BIOLOGIC AGENTS, RECEIVE CYTOMEGALOVIRUS CHEMOPROPHYLAXIS?**

**Rangaswamy, D**, D, **Kaza, S**, S, **Nagaraju, S**, S, **Attur, R**

Kasturba Medical College- Manipal University, Nephrology, Manipal, India; Kasturba Medical College, Nephrology, Manipal, India

**Introduction:** Cytomegalovirus (CMV) is a frequently encountered opportunistic pathogen in renal transplant recipients (RTR). Spectrum of CMV infection ranges from latent infection to life-threatening multisystem disease. Current KDIGO guidelines recommend RTR to receive a biologic induction agent and all RTR (except in D-/ R- CMV serology) to receive chemoprophylaxis for CMV infection with oral ganciclovir or valganciclovir for at least 3 months post transplantation. Currently no guidelines exist for use of CMV prophylaxis in patients transplanted without a biologic induction.